Global Genes Rare Disease Stock Index Rises 0.28% As New Year Begins

The Global Genes Rare Disease Stock Index finished a holiday-shortened first week of trading in the nuew year up 0.28 percent. All of the major indices had stronger closes with the Nasdaq Composite producing the strongest performance with a 3.38 percent gain for the week.


INDEX2017 Close12/29/171/8/18Week ChangeYTD CHANGE
GLOBAL GENES RARE DISEASE STOCK INDEX1232.321232.321235.770.28%0.28%
NYSE ARCA PHARMA544.93544.93559.012.58%2.58%
S&P 5002673.612673.612743.152.60%2.60%
NASDAQ COMP6903.396903.397136.563.38%3.38%
NASDAQ BIOTECH3356.613356.613,454.082.90%2.90%

The Global Genes Rare Disease Stock Index is a price-weighted index of a representative sample of rare disease drug developers whose shares trade on U.S. exchanges. The index had a value of 1,000 on December 30, 2016. The components include Alexion Pharmaceuticals (ALXN), Amicus Therapeutics (FOLD), Audentes Therapeutics (BOLD), AveXis (AVXS), BioMarin Pharmaceutical (BMRN), bluebird Bio (BLUE), Corbus Pharmaceuticals (CRBP), Idera Pharmaceuticals (IDRA), Intercept Pharmaceuticals (ICPT), Ionis Pharmacecuticals (IONS), PTC Therapeutics (PTCT), Sarepta Therapeutics, Spark Theraeptuics (ONCE), and Ultragenyx Pharmaceutical (RARE). 

Filed Under: Business, Data Center, Global Genes

Speak Your Mind